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Autism is a highly heritable neurodevelopmental disorder whose underlying genetic causes have yet to be identified.
To date, there have been eight genome screens for autism, two of which identified a putative susceptibility locus
on chromosome 16p. In the present study, 10 positional candidate genes that map to 16p11-13 were examined for
coding variants: A2BP1, ABAT, BFAR, CREBBP, EMP2, GRIN2A, MRTF-B, SSTR5, TBX6, and UBN1. Screening
of all coding and regulatory regions by denaturing high-performance liquid chromatography identified seven non-
synonymous changes. Five of these mutations were found to cosegregate with autism, but the mutations are not
predicted to have deleterious effects on protein structure and are unlikely to represent significant etiological variants.
Selected variants from candidate genes were genotyped in the entire International Molecular Genetics Study of
Autism Consortium collection of 239 multiplex families and were tested for association with autism by use of the
pedigree disequilibrium test. Additionally, genotype frequencies were compared between 239 unrelated affected
individuals and 192 controls. Patterns of linkage disequilibrium were investigated, and the transmission of haplotypes
across candidate genes was tested for association. Evidence of single-marker association was found for variants in
ABAT, CREBBP, and GRIN2A. Within these genes, 12 single-nucleotide polymorphisms (SNPs) were subsequently
genotyped in 91 autism trios (one affected individual and two unaffected parents), and the association was replicated
within GRIN2A (Fisher’s exact test, ). Logistic regression analysis of SNP data across GRIN2A and ABATP ! .0001
showed a trend toward haplotypic differences between cases and controls.
Introduction
Autism is a severe neurodevelopmental disorder that af-
fects reciprocal communication and social interaction and
is associated with repetitive and stereotyped behaviors.
Recent epidemiological studies have revised the popu-
lation prevalence of autism upward from 4 in 10,000 to
9–11 in 10,000 (Chakrabarti and Fombonne 2001; Fom-
bonne 2003), and the overall rate of pervasive devel-
opmental disorders is ∼60 in 10,000 (Fombonne 2002).
Autism is highly heritable and shows strong familial
clustering, with a l (sibling relative risk) of 75–100,
although the mode of inheritance is complex (Bailey et
al. 1995; Pickles et al. 1995). Autism is found in three-
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to-four times as many males as females, which suggests
a possible sex-linked effect, but multivariate analysis of
the phenotype in relatives does not support X-linked
inheritance (Pickles et al. 2000). Moderate evidence of
linkage to the X chromosome has been observed in two
genome screens (Liu et al. 2001; Shao et al. 2002). A
single mutation in each of the X-linked neuroligin genes
NLGN3 and NLGN4 has also been reported, but the
low frequency of the mutations makes it unlikely that
they contribute significantly to autism etiology (Jamain
et al. 2003; Stone et al. 2003; Vincent et al. 2004). Au-
tism is associated with phenotypes of known etiologies
in ∼6% of cases, including fragile-X syndrome, epilepsy,
neurofibromatosis, and tuberous sclerosis (Fombonne
2002). The increased comorbidity of these disorders
with autism may indicate a contribution to the autism
phenotype by disruption of a common neurological—
although not necessarily genetic—pathway.
Recently, the IMGSAC performed a whole-genome
screen of 83 affected sib pairs (ASPs). Thirteen loci that
displayed evidence of linkage were subsequently geno-
typed for 152 sib pairs (IMGSAC 2001). The three high-
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Table 1
Candidate Genes Screened for Autism-Susceptibility Variants
Gene Symbol Gene Name Positiona
GenBank
Accession
Number
Genomic Region
(kb)
mRNA
Length
(bp) No. of Exons
A2BP1 Ataxin 2–binding protein 6009132–7700843 NM_018723 420.449 2,279 16
ABAT 4-Aminobutyrate
aminotransferase
8675992–8782887 BC031413 106.895 1,705 14
BFAR Bifunctional apoptosis
regulator
14634296–14670193 NM_016561 35.898 2,531 8
CREBBP CREB-binding protein 3716569–3870712 NM_004380 154.144 8,694 32
EMP2 Epithelial membrane
protein 2
10533475–10582040 NM_001424 48.566 690 4
GRIN2A Glutamate receptor,
ionotropic, NMDA 2A
9762922–10184112 NM_000833 421.191 6,293 14
MRTF-B Myocardin-related
transcription factor B
14235623–14268130 NM_014048 32.508 7,815 8
SSTR5 Somatostatin receptor 5 1068869–1069964 NM_001053 1.096 1,095 1
TBX6 T-box 6 30004582–30010709 NM_004608 6.128 2,468 9
UBN1 Ubinuclein 1 4842216–4872364 NM_016936 30.149 5,747 18
a From the May 2004 release of the International Human Genome Sequencing Consortium.
Table 2
SNPs Genotyped in TSC2 and below ADHD
Linkage Peak
Genomic Region
anddbSNP Number Positiona Allele Variant
TSC2b:
rs2516740 2037111 GrT
rs2074968 2050572 GrC
rs1051771 2078585 GrC
ADHD linkage peakc:
rs153783 15509867 GrA
rs1125972 15514488 GrA
rs1065838 15535539 TrC
rs1107143 15594082 TrC
a From the May 2004 release of the International
Human Genome Sequencing Consortium.
b The distance between rs2516740 and rs2074968
is 13,461 bp; the distance between rs2074968 and
rs1051771 is 28,013 bp.
c The distance between rs153783 and rs1125972
is 4,621 bp; the distance between rs1125972 and
rs1065838 is 21,051 bp; the distance between
rs1065838 and rs1107143 is 58,543 bp.
est-scoring loci detected were on 2q21-33 at D2S2118,
with a multipoint maximum LOD score (MLS) of 3.74;
7q22.2-31.3 at D7S477, with a multipoint MLS of 3.20;
and 16p11-13 at D16S3102, with a multipoint MLS of
2.93. Detailed analysis of sex-specific and parent-of-ori-
gin effects at these loci has recently been reported (Lamb
et al. 2005). The linkage to chromosome 16p was found
in male-male ASPs (MLS of 2.48 for 145 male-male
ASPs vs. MLS of 0 for 74 male-female or female-female
ASPs) (Lamb et al. 2005). D16S3102 at the peak of
linkage was physically mapped at 12.46 Mb in the May
2004 release of the Human Genome Sequence. Linkage
overlapping the region on chromosome 16p, between
10 cM and 23 cM, has been reported by Philippe et al.
(1999), with a multipoint MLS of 0.74 at 10.6 cM
( multiplex families). Additionally, trisomy ofnp 51
16p and duplications mapping to 16p11.2 and 16p12.2
have been reported for individuals with autism traits
(Finelli et al. 2004).
To identify the autism-susceptibility gene at 16p11-
13, positional functional candidate genes were selected,
and their coding sequences were screened by denaturing
high-performance liquid chromatography (DHPLC) for
48 individuals (from multiplex families) who contributed
to linkage on 16p11-13. Variants detected by DHPLC
were further characterized by sequencing, and missense
variants were tested for cosegregation with autism. The
candidate genes that were examined in the present study
are described in table 1.
In total, 38 SNPs were selected for genotyping in 239
multiplex families and were tested for association by use
of the pedigree disequilibrium test (PDT). These included
three SNPs in TSC2; TSC2 maps to 16p13 and encodes
one of the genes that cause tuberous sclerosis, which has
been reported to be associated with autism. Following
the suggestion that there is a phenotypic overlap between
attention-deficit/hyperactivity disorder (ADHD) and au-
tism, four SNPs previously analyzed in a study of ADHD
that found linkage to chromosome 16p were also geno-
typed (Smalley et al. 2002; Ogdie et al. 2003, 2004),
as shown in table 2. All SNPs were also genotyped for
192 controls, and the allele and genotype frequencies
were compared with those of 239 unrelated affected
individuals. SNP data were analyzed for linkage dis-
equilibrium (LD), association with autism, and haplotype
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transmission disequilibrium. Twelve SNPs that showed
evidence of association were subsequently genotyped
for 91 autism trios (one affected individual and two
unaffected parents). Logistic regression analysis was per-
formed for haplotypes from genes containing SNPs that
showed evidence of association.
Description of Candidate Genes
GRIN2A (MIM 138253) and SSTR5 are cell-surface
receptors. GRIN2A encodes one of four N-methyl-D-
aspartate (NMDA) receptor 2 subunits that form an
NMDA-receptor channel. NMDA receptors have been
shown to be involved in long-term potentiation (LTP),
an activity associated with learning and memory. Tar-
geted disruption of the mouse homologue of GRIN2A,
GluR, reduces LTP and produces other behavioral defi-
cits (Sakimura et al. 1995). Evidence of association be-
tween a GRIN2A exon 5 polymorphism and ADHD has
also been reported recently (Turic et al. 2004). SSTR5
(MIM 182455) encodes a G-protein–coupled receptor for
the inhibitory hormonal regulator somatostatin. There
is evidence that somatostatin and its receptors are tran-
siently expressed in developing neurons; they are thought
to control cell migration. Lauritsen et al. (2003) have
performed analysis of 12 polymorphisms in SSTR5 in 79
families with autism but found no evidence of association.
Three of the genes screened are involved in transcrip-
tional regulation. TBX6 (MIM 602427) is a member of
the T-box family that encodes transcription factors in-
volved in the regulation of developmental processes and
is expressed in discrete embryonic domains (Papapetrou
et al. 1999). UBN1 encodes a ubiquitously expressed
nuclear protein found to interact with EB1 and c-Jun,
which, in turn, interact with cellular promoters and tran-
scription factors. CREBBP (MIM 600140) encodes a
large protein of 2,442 aa and binds specifically to the
protein-kinase-A–phosphorylated form of the CREB pro-
tein (Chrivia et al. 1993). CREBBP can activate tran-
scription through its C-terminus and acts to augment
the ability of phosphorylated CREB to activate cAMP-
responsive genes, interacting directly with transcription
factor IIB. Mutations in CREBBP are responsible for
Rubenstein-Taybi syndrome (RTS [MIM 180849]), which
is characterized by mental retardation and broad thumbs
and halluces. RTS has been associated with autism-like
features in a minority of cases (Hellings et al. 2002).
EMP2 (MIM 602334) and BFAR are involved in cell-
cycle control. EMP2 has high sequence similarity with
peripheral myelin protein 22, suggesting that it may have
a similar function in cell proliferation and cell-cell in-
teractions. BFAR encodes a protein that inhibits Bax-
induced and Fas-induced apoptosis (Itoh et al. 1993; Wei
et al. 2001).
The remaining three candidate genes were chosen be-
cause of their expression patterns and potential connec-
tion with neurological disease. ABAT (MIM 137150) is
responsible for the catabolism of gamma-aminobutyric
acid (GABA) into succinic semialdehyde (De Biase et al.
1995). GABA is an important inhibitory neurotransmitter
in the brain and is estimated to be present in 20%–50%
of human synapses. GABA is involved directly and in-
directly in the pathogenesis of many neurological dis-
eases, including convulsions, which may be relevant,
given that approximately one-third of individuals with
autism develop epilepsy (Fombonne 2002). A2BP1 (MIM
605104) possesses a ribonucleoprotein motif, which is
highly conserved among RNA-binding proteins. A2BP1
binds to the C-terminus of ataxin-2 and may contribute
to the pathology of spinocerebellar ataxia type 2 (SCA2
[MIM 183090]) (Shibata et al. 2000). MRTF-B was iden-
tified from cDNA libraries of size-fractioned adult and
fetal human brain (Nagase et al. 1999). MRTF-B is
highly expressed in the amygdala, caudate nucleus, hip-
pocampus, and fetal brain and was recently found to be
involved in muscle differentiation (Selvaraj and Prywes
2003).
Material and Methods
IMGSAC Family Collection
The IMGSAC has collected family data in successive
stages, and details of assessment protocols are described
elsewhere (IMGSAC 2001). To summarize, after an ini-
tial screen for medical disorders and a preliminary as-
sessment, parents were administered the Autism Diagnos-
tic Interview–Revised (ADI-R) and the Vineland Adaptive
Behavior Scales (Sparrow et al. 1984; Le Couteur et al.
1989). Probands were administered the Autism Diag-
nostic Observation Schedule (ADOS) (Lord et al. 2000),
and psychometric data were obtained. Affected individ-
uals also underwent a thorough medical examination so
that those with tuberous sclerosis and neurofibromatosis
could be excluded, and any morphological abnormalities
were recorded. All participating clinical sites followed
the same assessment protocol, and ADI-R and ADOS
consensus-coding meetings were held regularly by cli-
nicians. DNA was extracted from blood, buccal swabs,
or cell lines by use of the Nucleon kit and standard
techniques. Samples from one affected individual per
multiplex family were tested for fragile-X syndrome,
and, when possible, all affected individuals underwent
karyotypic analysis (Lamb et al. 2005). Relevant ethical
committees have reviewed this study.
The IMGSAC has collected a further 67 sibling pairs
since the publication of the completed genome screen,
for a total of 219 sibling pairs from 207 families. In
addition, 32 families containing extended relative pairs
have been collected. The male:female ratio of affected
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individuals is 3.9:1. One affected individual was selected
at random from each multiplex family, to create a group
of 239 affected unrelated individuals for case-control
analysis. A singleton sample consisting of 91 autism trios
with a clinical diagnosis of autism has also been col-
lected. The singleton sample consists of 22 trios from
Denmark, 37 trios from the Netherlands, and 32 trios
from the United Kingdom. Analysis of linkage data from
the IMGSAC sample on chromosomes 2,7, and 16 does
not indicate that country of origin significantly affects
either the magnitude or location of the linkage signal or
the evidence of association in the complete IMGSAC
sample (authors’ unpublished data) (Bonora et al. 2005).
Controls
Random controls from the European Collection of
Cell Cultures (ECACC) ( ) were used for SNPnp 192
typing. DNA was extracted at ECACC from lympho-
blastoid cell lines derived from white randomly selected
blood donors whose parents and grandparents were born
in the United Kingdom or Ireland. The control samples
were not characterized for autism phenotypes. Half of
the controls were male and half female. Although the
male:female ratio is different for cases and controls, only
the presence of a very strong sex-specific allelic effect
could reduce the ability to detect association. Linkage
analysis based on the sex of APSs on chromosome 16
shows some evidence of a sex-specific effect, but it is
unclear how this would affect the frequency of a disease-
causing variant (Lamb et al. 2005).
Mutation Screening
Intron-exon boundaries were characterized in silico
by use of National Center for Biotechnology Informa-
tion LocusLink and University of California–Santa Cruz
(UCSC) Golden Path (see UCSC Genome Browser Web
site). The mRNA sequence was subjected to BLAST analy-
sis, to determine or confirm genomic structure. Exon-spe-
cific primers were designed using Primer3. Large exons
and promoter regions were covered by overlapping PCR
products of ∼500 bp. PCRs were performed in a reaction
mixture containing 40 ng of DNA and final concentra-
tions of 2.5 mM KCl; 2.0, 2.5, or 3.0 mM MgCl2; 0.2
mM primer; 0.2 mM dNTPs; 0.9 U AmpliTaq Gold poly-
merase; and 0.1 U PfuTurbo (Stratagene). For GC-rich
products of 2.5%–10%, DMSO was used with a mix
of 0.2 mM dATP, dTTP, and dCTP; 0.1 mM dGTP;
and 0.1 mM 7-deaz-2′-deoxyguanosine-5′-triphosphate
(Amersham Pharmacia Biotech). The PCR consisted of
touchdown protocols with a maximum annealing tem-
perature of 50C–67.5C (T1) and a minimum annealing
temperature of 42.5C–60C (T2) (15 min at 95C, fol-
lowed by 14 cycles of 30 s at 95C, 30 s at T10.5C
per cycle, and 30 s at 72C, followed by 29 cycles of 30
s at 95C, 30 s at T2, and 30 s at 72C). PCR products
were denatured and reannealed using the following pro-
tocol: 4 min at 95C, 30 s at 95C, and 42 cycles of 30
s at 1.6C per cycle.
The Transgenomic WAVE DNA Fragment Analysis
System was used to detect heterozygous individuals by
DHPLC. Gradients were designed using WAVEMAKER
Software (version 4.1) and spanned a temperature range
of 51.5C–70C. Crude PCR products were loaded onto
the DNASep Column, and elution profiles were analyzed
for heteroduplex formation. Melting curves for fragments
containing c7dGTP were experimentally determined.
Variant Identification
Common variants were identified by sequencing seven
heteroduplex samples and a control sample with a homo-
duplex profile. Low-frequency variants were sequenced
for all individuals showing the heteroduplex profile and
for a control sample. Sequencing was performed with
BigDye Terminator mix on ABI 377 machines, in ac-
cordance with standard protocols, and variants were an-
alyzed with Sequence Analysis and Sequence Navigator.
SNP Typing
Mass-extension assay.—Primers and mass-extension
assays were designed for Sequenom SNP typing with
SpectroDESIGNER. PCRs were performed in 10-ml re-
actions with 8 ng of DNA template and final concen-
trations of 2.5 mM KCl and MgCl2, 200 mM dNTPs, 1
U of HotStarTaq Polymerase (Qiagen), and primer con-
centration of 0.15 mM. Multiplex PCRs were performed
using up to four primer pairs per reaction; 45 cycles of
20 s at 95C, 30 s at 56C, and 1 min at 72C were
performed. Nonincorporated dNTPs were removed with
shrimp alkaline phosphatase for 20 min at 37C and for
5 min at 85C. The mass-extension reaction was per-
formed using MassEXTEND enzymes—thermosequen-
ase, hME termination mixes, and hME extension prim-
ers; 55 cycles were performed for 5 s at 94C, for 5 s
at 52C, and for 5 s at 72C. Unincorporated ddNTPs
and dNTPs were removed with SpectroCLEAN resin,
and products were transferred to a 384 SpectroCHIP by
use of the SpectroPOINT robot. The chip was read using
the Bruker Biflex III Mass Spectrometer system. Seque-
nom Genotype Analyzer was used to manually check
failed genotypes and to assign alleles, when possible.
Data either were exported from SpectroTYPER using
Report Generator or were directly streamed into the
Wellcome Trust Centre for Human Genetics Laboratory
Information Management System Integrated Genotyp-
ing System (IGS).
Restriction digest.—PCR for ABAT exon 2 was per-
formed in 10-ml reactions containing 24 ng of DNA and
final concentrations of 2.5 mM KCl, 2.5 mM MgCl2,
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0.2 mM primer, 0.2 mM dNTPs, and 0.25 U AmpliTaq
Gold polymerase. Touchdown PCR was performed with
a maximum annealing temperature of 62.5C. PCR prod-
uct from each plate was tested on agarose and was in-
cubated with 0.1 U of BsoB1 and 2 ml of buffer 2 (New
England BioLabs), in a total volume of 20 ml at 37C for
6 h. Digested products were visualized on a 3% agarose
gel. Digests were genotyped blind to affection status and
were entered into the IGS.
Statistical Analysis
Association analysis.—The PDT was used to test for
transmission disequilibrium (Martin et al. 2000) for the
multiplex and singleton samples. This test is more pow-
erful than the transmission/disequilibrium test (TDT) for
the multiplex sample and analyzes informative branches
of extended families with all available data. The PDT
retains the within-family nature of the TDT and provides
a valid test for association, even in the presence of popu-
lation substructure. A test for the transmission disequi-
librium of genotypes—rather than alleles—was also per-
formed using the geno-PDT, an extension of the PDT
(Martin et al. 2003a). Case-control association analysis
was performed using related cases from the multiplex
families and controls, as proposed by Slager and Schaid
(2001). This test accounts for the biological relationship
between cases and compares genotype frequencies be-
tween cases and controls by comparing the trend in pro-
portions as the dosage of the risk allele increases. Ge-
notype-frequency differences between unrelated affected
cases from the multiplex and singleton samples and con-
trols were analyzed using Fisher’s exact test for count
data.
Haplotype analysis.—Haplotypes were determined us-
ing PHASE v2.0.2 for groups of SNPs within candidate
genes. Any genotypes that were not assigned phase with
190% certainty were disregarded. Because PHASE v2.02
reconstructs haplotypes from population genotype data,
two rounds of haplotype reconstruction were performed.
First, multiplex case and control data were analyzed to-
gether, and, second, singleton case and control data were
analyzed together, with the result of small differences
in the numbers of haplotypes constructed for controls.
PHASE v2.0.2 was selected instead of GENEHUNTER
2.0 for determination of haplotypes, because PHASE
v2.0.2 does not assume linkage equilibrium over short
distances and can be used to generate haplotypes for in-
dividuals without parental genotypes. Haplotype analysis
was performed using TRANSMIT for both multiplex and
singleton data (Clayton and Jones 1999). TRANSMIT
implements a TDT that analyzes the transmission of
multilocus haplotypes and has good power when pa-
rental genotypes are available, as is the case in this sam-
ple (∼80%) (Martin et al. 2003b). For each haplotype,
a x2 test with 1 df for excess transmission is produced.
A global test for association is also produced with H
df ( of haplotypes for which information1 Hp number
is available).
Logistic regression analysis.—Logistic regression an-
alysis of haplotype data was performed with the pro-
gram R (R Project for Statistical Computing), as de-
scribed by Wallenstein et al. (1998). Unrelated affected
individuals from the multiplex and singleton families,
identical to those used in the case-control analyses, were
used in the logistic regression analysis. They impose an
assumption of additivity on the haplotype analysis, thus
providing predictor variables that include the number of
copies (0, 1, or 2) of each haplotype and that yield a
logistic regression for which the outcome is either case
or control. The model is constructed so that each co-
efficient gives the log odds ratio for disease for an in-
dividual with a single copy of the relevant haplotype and
another copy of the baseline haplotype, compared with
an individual with two copies of a baseline haplotype.
Models were fitted in which each gene (ABAT, CREBBP,
GRIN2A, and TSC2) was tested alone and jointly. Ge-
notypes for an individual (i.e., the pairs of haplotypes)
are denoted as (x;y).
LD mapping.—Haplotype files were analyzed using
HaploXT to generate an output file describing LD (Abe-
casis and Cookson 2000). Individual marker-by-marker
contingency tables were produced and imported into the
Graphical Overview of Linkage Disequilibrium (GOLD)
program. Lewontin’s standardized disequilibrium coef-
ficient D′ was used (Lewontin and Kojima 1960), be-
cause it accounts for allele frequency, although, like
other measures of LD, it may be artificially inflated by
rare haplotypes.
Error detection.—Mendelian consistency of SNP geno-
type data was checked using PedCheck (O’Connell and
Weeks 1998), and any inconsistent genotypes were re-
moved. Data were prepared for statistical analysis by use
of Mega2 (Mukhopadhyay et al. 1999; see the University
of Pittsburgh Department of Human Genetics Web site).
Genotypes flanking double recombinants, detected after
running GENEHUNTER 2.0, were checked and disre-
garded if ambiguous. SIBMED (sib-pair mutation error
detection) was also used to remove possible genotyping
errors (Douglas et al. 2000).
Permutation of affection status: Fisher’s exact test.—An
empirical experimentwise P value for association, to al-
low for multiple testing across all 28 SNPs, was obtained
by random permutations of case and control status. For
each permutation, the minimum P value from Fisher’s
exact test across all SNPs was recorded. An empirical
estimate of the experimentwise P value was then given
by the proportion of permutations for which the mini-
mum P value exceeded that obtained for the original
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Table 3
Missense Mutations in Candidate Genes Identified by DHPLC
GENE
AND EXONa
cDNA
NUCLEOTIDE
WILD-TYPE/
VARIANT ALLELE
AMINO ACID
SUBSTITUTION
NO. OF
HETEROZYGOTES
IN SCREENED
SAMPLES
( )np 48
MINOR-ALLELE FREQUENCY
IN
Multiplex Cases
( )np 239
Controls
( )np 192
ABAT:
2 208 A/G G56R 21 .457 .369
BFAR:
3 563 G/T M140R 6 .332 .388
6 1096 A/G V315I 2 .018 .077
MRTF-B:
5 1624 C/G N543K 1 .024 .035
SSTR5:
1 92 C/T T333I 1 NDb NDb
UBN1:
3 422 A/C A103N 1 .004 .000
9 1413 G/A Y435C 2 .031 .027
a SNPs genotyped in the entire IMGSAC sample and controls for all but exon 1.
b NDpno data were available.
sample. The same procedure was repeated for the sin-
gleton cases and controls.
Permutation of affection status: logistic regression an-
alysis.—To test the significance of the logistic haplotype
regression analysis of the four genes, with consideration
of multiple testing, PHASE v2.0.2 was used to generate
“best pair” haplotypes for cases and controls; affection
status was then permuted 10,000 times. An additive
logistic regression model incorporating the joint haplo-
typic effects across ABAT, CREBBP, GRIN2A, and TSC2
was fitted to the permuted data, and P values were re-
corded. The significance of the joint model was estimated
as the proportion of permutations in which the regres-
sion P value was smaller than that observed in the joint
analysis of the original sample data.
Bioinformatic Analysis
Variants found within 20 bp of intron-exon bound-
aries were analyzed for possible effects on splice-site sig-
nal by use of sequence analysis tools available at the
Berkeley Drosophila Genome Project Web site (Brunak
et al. 1991; Kulp et al. 1997). Variants within exons
were analyzed for possible changes to exon-splice en-
hancers by use of the ESEfinder interface (Cartegni et
al. 2003). The program Pfam was used to determine the
location of coding variants within known protein do-
mains (Bateman et al. 2004). Homology searches by use
of PolyPhen were performed to determine the extent of
conservation at the position of missense mutations in
known sequences (Sunyaev et al. 2001). PolyPhen uses
empirical rules and structural information to character-
ize the effect of an amino acid substitution.
Results
Failure Rates and Error Checking
Of the 38 SNPs initially selected for genotyping, 10
were disregarded because of failing multiplex PCR, fail-
ing extension reaction, poor success rate, or a weak ex-
tension assay. Additionally, the A/G SNP causing the
G56R substitution in ABAT was genotyped by restric-
tion enzyme digestion because of spurious heterozygotes
in the mass-extension assay. Of a total of 47,646 SNP
genotyping assays performed, 44,647 genotypes were gen-
erated, a 93.7% success rate. Analysis with PedCheck led
to the removal of 35 genotypes from the IMGSAC data
(0.08% error rate). Most of these were due to noncon-
servative SNP genotyping allele calls from the Sequenom
Genotype Analyzer. Checking for double recombinants
resulted in the removal of an additional 26 genotypes.
All markers were analyzed for Hardy-Weinberg equilib-
rium and were not found to deviate from expected allele
frequencies ( ); a small number of markers withP ! .01
low heterozygosity did deviate from expected allele fre-
quencies ( ), but this is likely to be due to chance.P ! .05
Finally, SIBMED was run with all SNP data, and mi-
crosatellite data were generated from the completion of
the IMGSAC genome screen; an additional 14 low-prob-
ability genotypes were removed.
Mutation Screening
Seven missense variants were detected during muta-
tion screening of the coding sequence, as described in
table 3. Additionally, 108 noncoding/silent variants were
found, as shown in table 4. Several missense variants were
found in a single family; the T333I change in SSTR5
Table 4
Nonmissense Variants in Candidate Genes Identified by DHPLC
GENE,
LOCATION,
AND CDNA
NUCLEOTIDE
MAJOR/MINOR
ALLELE
NO. OF
HETEROZYGOTES
IN SCREENED
SAMPLES
( )np 48
MINOR-ALLELE
FREQUENCYa IN
Cases Controls
A2BP1:
Intron 1:
7306 /CTT del 2 … …
Intron 2:
80447 A/C 24 … …
80448 A/T 24 … …
Intron 3:
85220 /T del 23 … …
Exon 5:
1067 C/G 2 … …
1098 G/A 2 … …
Intron 5:
118225 A/C 4 … …
Exon 6b:
1271 A/G 1 .021 .003
Intron 7:
1379109 A/G 1 … …
Intron 11:
167317 /CT ins 21 … …
Intron 13:
18319 A/G 2 … …
Intron 15b:
19733 A/G 6 .004 0
3′ UTR:
2102141 G/T 23 … …
ABAT:
Intron 1b:
10249 T/C 15 .391 .2952
Intron 2:
20911 A/G 1 … …
21068 C/A 1 … …
2105 C/T 1 … …
Exon 4b:
350 C/T 10 … …
Intron 8:
58214 /CA ins 5 … …
58254 A/C 2 … …
Exon 9:
685 C/T 1 … …
Exon 12:
995 A/C 2 … …
Intron 13:
1313120 /G ins 10 … …
Intron 14:
14239 C/T 22 … …
3′ UTR:
154471 A/G 1 … …
BFAR:
Exon 1:
50 T/C 1 … …
Intron 1:
89105 G/A 4 … …
Exon 2:
178 T/A 1 … …
Intron 6:
93784 /GTG ins 1 … …
3′ UTR:
1507794 A/G 1 … …
1507795 G/C 1 … …
(continued)
Table 4 (continued)
GENE,
LOCATION,
AND CDNA
NUCLEOTIDE
MAJOR/MINOR
ALLELE
NO. OF
HETEROZYGOTES
IN SCREENED
SAMPLES
( )np 48
MINOR-ALLELE
FREQUENCYa IN
Cases Controls
CREBBP:
Exon 3:
258 G/A 1 … …
Exon 4:
1037 T/C 3 … …
Intron 3b,c:
19958585 T/C NDd .005 0
Intron 4:
117476 /TTTG del 1 … …
Intron 6:
153031 G/T 3 … …
Intron 7b,c:
1730215 G/A NDd .349 .363
173158 A/C 1 … …
Exon 11:
2152 T/C 1 … …
Intron 11b:
231178 C/T 3 .077 .007
Intron 13:
235859 T/C 1 … …
Intron 17b:
34496163 C/T 23 .414 .522
Intron 20b,c:
38983049 C/T NDd .033 .015
Intron 22b:
40408 T/C 3 .014 .022
Exon 23:
4097 A/C 1 … …
Intron 26b,c:
448042 G/A 11 .027 .015
Intron 29b:
493719 C/G 3 .028 .019
Exon 31:
5160 A/C 2 … …
Exon 32:
7411 G/A 3 … …
3′ UTR:
752526 /C ins 2 … …
EMP2:
Exon 2:
53 G/C 7 … …
Exon 3:
172 C/T 15 … …
205 G/A 23 … …
245 C/T 23 … …
3′ UTR:
Unidentified Unidentified 13 … …
GRIN2A:
Intron 1:
11233 C/T 27 … …
Intron 5:
131815 G/C 1 … …
Exon 6b:
1576 T/C 21 .424 .597
Intron 7:
180829 G/C 1 … …
Intron 8:
196431 /GA ins 25 … …
Intron 10b:
231635 G/C 25 .447 .381
Intron 11:
231621 /GA ins 1 … …
(continued)
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Table 4 (continued)
GENE,
LOCATION,
AND CDNA
NUCLEOTIDE
MAJOR/MINOR
ALLELE
NO. OF
HETEROZYGOTES
IN SCREENED
SAMPLES
( )np 48
MINOR-ALLELE
FREQUENCYa IN
Cases Controls
Exon 11:
2396 G/A 2 … …
Exon 14:
3539 G/T 2 … …
3′ UTRb:
470539 C/A 2 .005 .014
41051213 A/G 26 .298 .510
MRTF-B:
Exon 1:
90 G/C 1 … …
Exon 2:
379 T/G 1 … …
Intron 3:
147512 G/T 2 … …
Intron 4:
151321 C/T 1 … …
3′ UTRb:
248767 T/C 1 … …
2487561 T/C 1 … …
24871110 G/C 1 … …
24871441 T/A 1 … …
24871713 A/C 1 … …
24871849 G/T 1 … …
TBX6:
5′ UTR:
1206 A/G 3 … …
Intron 7:
9384 C/T 20 … …
93719 /GAT ins 23 … …
Exon 8:
1252 A/G 1 … …
Intron 8:
1335428 G/C 1 … …
UBN1:
5′ UTR:
117 C/G 7 … …
Intron 1:
75109 TA/AG 3 … …
7563 T/C 3 … …
7521 A/G 6 … …
7426 T/C 3 … …
7540 T/G 25 … …
7468 G/T 2 … …
Exon 3:
147 A/G 2 … …
Intron 3:
45422 A/G 2 … …
Intron 4:
5463 G/A 4 … …
Exon 5:
5995 C/T 11 … …
Intron 6:
7848 G/A 1 … …
Intron 9:
129611 /G ins 1 … …
129639 /TT del 1 … …
142562 C/T 3 … …
Intron 14:
191517 A/G 15 … …
191553 A/G 2 … …
(continued)
Table 4 (continued)
GENE,
LOCATION,
AND CDNA
NUCLEOTIDE
MAJOR/MINOR
ALLELE
NO. OF
HETEROZYGOTES
IN SCREENED
SAMPLES
( )np 48
MINOR-ALLELE
FREQUENCYa IN
Cases Controls
Exon 15:
2743 T/G 7 … …
2994 T/G 6 … …
Exon 18:
3486 C/T 3 … …
35191006 C/T 12 … …
3′ UTR:
3519157 T/C 7 … …
35191008 /C ins 1 … …
35191889 C/T 4 … …
35192302 C/G 1 … …
Exon 18:
35192588 A/C 13 … …
35192660 C/T 26 … …
a No data were available unless values are shown. For cases, ; fornp 239
controls, .np 192
b SNPs genotyped in the entire IMGSAC sample and controls.
c SNPs identified through dbSNP or Sequenom’s RealSNP Array.
d NDpno data were available.
was found in an unaffected mother, and the N543K mis-
sense variant in MRTF-B was paternally transmitted to
one of two affected sons. Bioinformatic analysis indi-
cated that these variants do not occur in any known
functional domain and that they were predicted to have
a benign effect. However, there are few homologous se-
quences available for thorough conservation analysis of
MRTF-B. Two missense variants were detected in BFAR.
During screening, the first missense variant in exon 3,
M140R, was found in six individuals and cosegregated
with autism in these families, although three parents
were found to be homozygous for arginine. The second
missense variant in BFAR, V315I, was detected, during
screening, in two individuals and cosegregated with au-
tism in both families. Bioinformatic analysis of the mis-
sense variants in BFAR showed that they were likely to
have only a benign effect on protein structure and that
they do not occur at highly conserved residues. Two rare
variants were found in UBN1. The A103N variant in
exon 3 was detected in one family and was transmitted
paternally to two affected offspring. This variant is in a
region of low complexity without a strong domain iden-
tity. A variant in exon 9, Y435C, was detected in two
individuals but cosegregated with autism in only one
family. Although this variant was predicted to have a
potentially harmful effect on protein function, no ho-
mologous sequences were available, and detailed com-
parative analysis was not possible.
One missense variant was found at a high frequency
in ABAT exon 2. However, the G56R change is distant
from the enzyme’s catalytic site and is unlikely to hinder
protein function. Sequence homology analysis also pre-
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dicted that the variant is likely to be benign. All of the
missense variants detected during screening, except that
in SSTR5, were typed in the entire IMGSAC sample and
192 controls. No evidence of transmission disequilib-
rium was found, and no significant differences in case-
control allele frequencies were observed for these mis-
sense variants, as shown in table 3. None of the variants
detected by DHPLC within 20 bp of the intron/exon
splice site were found to potentially affect splice signal.
Association Analysis and Logistic Regression Analysis
for Candidate Genes
Twenty-eight SNPs were successfully genotyped in the
IMGSAC families and controls, as shown in table 5. The
family data were analyzed for allele and genotype trans-
mission disequilibrium by use of the PDT. Fisher’s exact
test for count data was used to compare genotypes ob-
served in cases and controls. Additionally, multiplex ge-
notype data were compared with controls by use of a
trend test that accounts for relatedness between affected
individuals. No significant evidence of association was
found with these tests either for SNPs in A2BP1, BFAR,
MRTF-B, TSC2, and UBN1 or for SNPs within the re-
gion of linkage with ADHD, as described in table 5.
SNPs within ABAT, GRIN2A, TSC2, and CREBBP
were analyzed for LD, to determine whether any hap-
lotype blocks were present in the data. The SNPs within
ABAT and GRIN2A were in strong LD with each other
( ), whereas there was variability in LD′D p 0.667–1
between SNPs in TSC2 and CREBBP. Because of the
manner in which most of the SNPs were identified and
the comparatively large inter-SNP distances, it is unlikely
that any underlying haplotype-block structure is fully
described by these analyses. But, given the evidence of
LD between SNPs in candidate genes, haplotype trans-
mission analysis was performed. No evidence of haplo-
type transmission disequilibrium was detected, using
TRANSMIT, in the IMGSAC families, although an ex-
haustive analysis of all possible SNP combinations was
not performed. There was evidence of association with
SNPs genotyped in ABAT, CREBBP, and GRIN2A, and
further logistic regression analysis was performed, as de-
scribed below. The logistic regression analysis performed
does not rely on any LD between SNPs and assesses only
the risk of being affected, given a particular genotype.
Haplotypes are described as sequential SNP alleles across
the candidate genes, with alleles labeled as in table 5
(e.g., haplotype h12 for ABAT describes allele 1 at
rs1731017, followed by allele 2 at the SNP within exon
2 of the gene).
ABAT.—Both SNPs within ABAT showed some evi-
dence of association in the multiplex sample, with the
trend-test and case-control analysis. The strongest evi-
dence of association was from the SNP within ABAT
intron 1, which, when analyzed using the trend test, in-
dicated that allele 2 was responsible for increasing the
risk of autism ( ). Fisher’s exact test for countP ! .001
data gave a P value of .0089, which indicates a signifi-
cant difference in genotype distribution between cases
and controls, as shown in table 5. This result was sup-
ported by the analysis of the same SNP in the singleton
sample with use of Fisher’s exact test ( ), asPp .0112
shown in table 5. Logistic regression of SNPs within
ABAT did not indicate that a particular haplotype sig-
nificantly increased the risk of autism, although there is
an overall difference in haplotype distribution between
cases, from the multiplex and singleton samples, and
controls ( ; for multiplex2 4x p 20.37 Pp 1.422# 10
cases; ; for singleton cases), as2x p 6.18 Pp .1031
shown in table 6. An additional SNP was also genotyped
in exon 4 of ABAT but was excluded from the final
analysis, despite supporting the results described above,
because of a low genotyping success rate (65.9% in the
multiplex sample; 73.9% in the singleton sample).
CREBBP.—In the multiplex sample, association was
found for CREBBP with two SNPs within introns 22
and 29, with use of the geno-PDT ( andPp .0363
, respectively) and with use of the allelic PDTPp .001
( and , respectively). However, bothPp .0074 Pp .0024
these SNPs had a minor-allele frequency !6%, and the
number of transmissions to affected individuals was
small. There was some additional evidence of association
from the trend test for the SNP in intron 17 (Pp
), but these results were not replicated in the sin-.0103
gleton sample. Conversely, SNPs within introns 7 and
20 showed evidence of association in the singleton sam-
ple ( and , respectively) but notPp .03078 Pp .0196
in the multiplex sample. It should be noted that the
minor-allele frequency was also low for the SNP in in-
tron 20, and the P value was of marginal significance
for the SNP in intron 7; it is likely these represent chance
findings. These results are shown in table 5. There was
no evidence from the logistic regression analysis to sup-
port the presence of a risk haplotype across CREBBP,
as shown in table 6.
GRIN2A.—One SNP in GRIN2A intron 10 showed
some evidence of transmission disequilibrium with the
geno-PDT ( ) and the trend test ( ).Pp .013 Pp .0337
This was supported by SNPs within exon 6 and the 3′
UTR that also showed evidence of association with the
trend test and case-control analysis, as shown in table
5. Although the singleton analysis does appear to sup-
port these results, closer inspection shows that the trans-
mission of different genotypes is responsible for the sig-
nificant result for the SNP within exon 6—genotype 1/1
in the singleton sample compared with genotype 1/2 in
the multiplex sample, as shown in table 5. A significant
difference in the distribution of haplotypes, between cases
and controls, was found using logistic regression analysis
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Table 6
Haplotype Logistic Regression Analysis
GENE AND
HAPLOTYPE
NO. OF
MULTIPLEX
LOG RELATIVE
RISK SE P (1FzF) x2 P dfCasesa Controlsb
ABAT: 20.37 1.4226#104 3
h11c 18 7 .8226 .1246
h12 162 85 .1536 .4397 .0727
h21 225 219 .726 .4209 .0845
h22 15 3 .7212 .7466 .334
CREBBP: 16.52 .0355 8
h12122222c 7 3 1.3986 .242
h21121212 5 0 14.6899 649.2732 .982
h21221212 4 5 .9564 .9743 .326
h22112222 4 2 .1661 1.1172 .882
h22121212 71 85 .9602 .7079 .175
h22121222 28 32 .9925 .7698 .197
h22122212 118 93 .7084 .7217 .326
h22122222 51 38 .662 .732 .366
Otherd 10 2 .6144 1.0274 .558
GRIN2A: 62.05 111.7232# 10 6
h1111c 34 42 .4716 .0103e
h1112 5 3 1.4334 .8411 .0883
h1122 168 73 .8251 .3143 .0086f
h2111 217 85 1.5479 .306 f74.21# 10
h2121 2 20 2.5906 .791 .001b
h2122 13 7 .4442 .5331 .4047
Otherd 5 2 1.3741 .9345 .1414
TSC2: 1.63 .8033 4
h112c 135 103 .22961 .22
h122 178 142 .0364 .1733 .834
h212 13 6 .4427 .5116 .387
h222 45 33 .012 .2326 .959
Otherd 3 4 .5625 .783 .472
NO. OF
SINGLETON
LOG RELATIVE
RISK SE P (1FzF) x2 P dfCasesa Controlsb
ABAT: 6.18 .1031 3
h11c 2 7 1.6134 .2746
h12 55 106 .4878 .8411 .562
h21 120 244 .5369 .8129 .509
h22 7 3 2.122 1.0626 .0458
CREBBP: 9.77 .1346 6
h12122222c 4 2 1.5728 .422
h21221212 0 5 16.7436 1,072.0759 .988
h22121212 35 86 1.0608 .8039 .187
h22121222 12 33 1.2422 .8471 .143
h22122212 49 96 1.013 .8081 .21
h22122222 30 40 .6101 .8348 .465
Otherd 2 6 1.4596 1.1374 .199
GRIN2A: 37.05 75.8528# 10 5
h1111c 22 42 .5113 .138
h1122 38 72 .2564 .3701 .4885
h2111 72 83 .7756 .3248 .0169f
h2121 0 20 17.5343 877.517 .9841
h2122 4 7 .4984 .6939 .4726
Otherd 0 4 16.6823 1,972.8826 .9933
a .np 239
b .np 192
c Referent haplotype.
d Haplotypes combined when !5.
e Haplotype has a protective effect .P ! .05
f Haplotype has a deleterious effect .P ! .05
Barnby et al.: Autism Candidate-Gene Analysis on Chromosome 16p 961
for both the multiplex and singleton samples ( 2x p
; ) compared with controls1162.05 Pp 1.7232# 10
( ; ). Haplotype h2111—2 7x p 37.05 Pp 5.8528# 10
genotypes , —significantly in-xp (2,1,1,1) yp (1,1,1,1)
creased the chances of being affected ( ),7Pp 4.21# 10
as did haplotype h1122— —xp (1,1,2,2),yp (1,1,1,1)
although not as strongly ( ), as shown in ta-Pp .0086
ble 6. The effect of the h2111 haplotype was replicated
in the singleton sample but at a less significant level
( ). Additionally, haplotype h2121—genotypesPp .0169
, —is found at a rate of 20/xp (1,2,1,2) yp (1,1,1,1)
232 in controls, compared with 2/580 in multiplex cases,
and appears to decrease the chances of being affected
( ).Pp .001
Statistical significance of association and logistic re-
gression analysis.—A simple Bonferroni correction, to
reduce the chance of type 1 error to 0.05 across all tests,
gives a significance threshold of .00714, if we consider
that seven tests were performed: geno-PDT, allelic PDT,
trend test for high-risk alleles 1 and 2, trend test for
high-risk allele 1, and trend test for high-risk allele 2,
Fisher’s exact test, and logistic regression analysis. To
reduce type 1 error to 0.001 across all tests, a Bonferroni
significance threshold of .000142 is required. This rep-
resents a highly conservative correction, given that the
PDTs and trend tests are correlated, although a number
of the results in table 5 do exceed these significance
levels.
Permutation tests, which provide more-accurate sig-
nificance thresholds, were performed (see the “Material
and Methods” section). For the single-point analysis
with Fisher’s exact test across 28 SNPs, the minimum P
value of for rs1014531 in GRIN2A in the72.9# 10
multiplex case-control analysis was smaller than any ob-
tained in 10,000 permutations, for an empirical P value
of . Similarly, for the joint logistic haplotype re-4! 10
gression of all four genes, the observed x2 statistic of
102.9 with 34 df (nominal ) was greater9Pp 7.4# 10
than for all 10,000 permutations; that is, an empirical
P value of .4! 10
Separate haplotype logistic analysis of the four genes
indicates that GRIN2A has by far the most significant
contribution. A test comparing the fit of GRIN2A alone
with that of all four genes gave a x2 value of 47.44 with
25 df ( ), which suggests that, whereas theP ! .0043
GRIN2A haplotypes are the principal contributors, there
may be some effect associated with the ABAT haplotypes.
Discussion
Seven missense variants were detected during the screen-
ing of 10 positional candidate genes on chromosome
16p11-13 for autism. Although a number of these vari-
ants cosegregated with autism, both their presence at
similar frequencies in controls and the lack of evidence
of transmission disequilibrium suggest that they are un-
likely to make a significant contribution to the etiology
of autism.
A large number of noncoding and silent mutations
were detected, but these are not predicted to alter splice-
site recognition sequences. However, bioinformatic an-
alysis alone may be insufficient to detect the effects of
intronic and silent variants on splicing and transcrip-
tional efficiency, as recently reported for CFTR and
SLC22A4 (Pagani et al. 2003; Tokuhiro et al. 2003),
and it is possible that novel regulatory elements could
be disrupted. A lack of missense mutations in coding
sequence does not preclude the presence of harmful non-
coding variants within a candidate gene. In fact, for a
multigenic disorder such as autism, more subtle changes
in gene regulation and expression are anticipated. This
has been found for PAD14, a gene associated with rheu-
matoid arthritis (Suzuki et al. 2003). Suzuki et al. (2003)
failed to detect any missense mutations in 48 affected
individuals but found a functional SNP haplotype af-
fecting mRNA stability.
The 28 SNPs genotyped in the IMGSAC families are
unlikely to provide sufficient coverage of the genomic
regions to conclusively exclude genes by association
mapping. This was particularly true for genes such as
A2BP1, which has a genomic region of 1,690 kb, from
which only two SNPs with low heterozygosities were
genotyped. Although a number of the SNPs genotyped
in this study had low heterozygosities, it has been argued
that they are useful for detecting association between
disease variants with more-recent origins, despite re-
duced informativeness (Pritchard and Cox 2002). Ad-
ditionally, even though most of the SNPs were success-
fully genotyped in 85% of individuals, the SNP-geno-
typing success rates had a range of 54.3%–98.1%. Al-
though this failure rate could reduce confidence in the
data used for analysis, Sequenom traces were manually
inspected for markers with low success rates, and low-
probability genotypes were removed when identified by
software programs.
The association analysis performed in this study at-
tempts to extract the maximum information from the
data available and is, in some respects, exploratory.
Family-based and case-control association analyses were
performed for single-marker and multimarker haplo-
types. Although this requires multiple testing of the
data, it has been suggested that different approaches
have varying power, depending on disease and marker-
allele frequency. A family-based analysis benefits when
parental genotypes are used as controls but may yield
little informative data if marker heterozygosity is low
and parental data is missing. Conversely, a case-control
analysis may have more power at varying allele fre-
quencies for the number of individuals genotyped but
could provide an artifactual result because of popu-
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lation-specific differences between cases and controls
(Risch and Teng 1998). It has also been suggested that
the added information from haplotype analysis of SNPs
has more power than single-marker analysis (Zaykin et
al. 2002). A number of procedures have been suggested
for correcting for multiple testing, including Bonferroni
correction, but there is as yet little consensus as to an
“ideal statistical framework” either for reporting P val-
ues or for analysis of SNP data (Roeder et al. 2005).
We have presented raw P values uncorrected for mul-
tiple testing, but the significance of reported P values
should be viewed with caution, given the number of
statistical tests performed.
Empirical significance levels were determined by per-
mutation of affection status for statistical tests involving
cases and controls. These levels suggest that the results
for the SNPs within GRIN2A for rs1014531 (Pp
) in the multiplex case-control analysis and72.9# 10
for intron 10 ( ) in the singleton case-12Pp 2.32# 10
control analysis are significant results. Additionally, the
logistic regression analysis suggests GRIN2A haplotypes
are significant contributors to genetic risk for autism.
Determining empirical P values for the family-based
tests for association, such as the PDT, requires corre-
lations between transmitted alleles within pedigrees to
be preserved, and “[i]t is not clear whether a simple
permutation procedure can be developed for this pur-
pose in general pedigrees” (Martin et al. 2000, p. 153).
Additionally, simple permutation of affection status is
inappropriate for the trend test, because the correlation
between alleles in related cases must be preserved (Slager
and Schaid 2001). Interpreting the results from these
statistical tests is challenging, but, on balance, the stron-
gest evidence of association with autism comes princi-
pally from GRIN2A, with ABAT accounting for the
remaining association.
Both SNPs genotyped in ABAT have genotypes asso-
ciated with autism in the case-control analysis of the
multiplex sample, with use of Fisher’s exact test for count
data (Fisher’s exact test provides more power than the
PDT, given the sample sizes). The result for the intron
1 SNP was also replicated in the singleton sample. The
result is further supported by the logistic regression
analysis, which indicates a difference in haplotype dis-
tribution between cases and controls. ABAT is a good
positional functional candidate for autism, especially
given its involvement in the catabolism of GABA, which
is known to be involved in neurological disease (Wong
et al. 2003). Other genes involved in this pathway have
been studied elsewhere, including the GABA receptor
subunit b3 (GABRB3) on 15q11-13, following reports
of chromosomal abnormalities in autistic individuals. A
number of studies have been published on the role of
this pathway in autism (reviewed by Veenstra-Vander-
Weele and Cook [2004]).
Screening the coding sequence of ABAT revealed one
high-frequency missense mutation, but this does not oc-
cur in a highly conserved position and was less strongly
associated with autism, compared with the SNP within
intron 1. It seems likely that any variants influencing
the expression of ABAT in individuals with autism are
located outside of the coding sequence within regulatory
regions.
No missense variants were detected by DHPLC in
GRIN2A. However, SNPs within GRIN2A gave strong
evidence of association in the case-control analysis of
the multiplex and singleton samples. There was also
some evidence of transmission disequilibrium with the
SNP in intron 10 in PDT results. Additionally, the lo-
gistic regression analysis found a significant difference
in haplotype distribution between cases and controls.
GRIN2A is an interesting candidate gene for autism,
given its role in learning and memory and the evidence
from mouse models of a complex behavioral phenotype
(Bannerman et al. 2004). There is also evidence, from
postmortem analysis, of expression differences in the
glutamate system between cerebella of subjects with au-
tism and of controls (Purcell et al. 2001). Variants with-
in GRIN2A may also confer increased risk for ADHD,
which indicates involvement in behavioral disorders
(Turic et al. 2004).
The candidate-gene analysis presented here is sub-
stantial but not completely exhaustive. Candidate genes
were screened for coding variants, and association an-
alysis was performed, but additional SNPs with inter-
SNP distances of 5–10 kb may be required to conclu-
sively discount these genes having a role in autism sus-
ceptibility (Kruglyak 1999). Increasing the density of
SNPs across candidate genes, on the basis of known
patterns of LD, to capture the maximum information
about haplotypic diversity is now increasingly feasible,
as data become available from the International Hap-
Map Project. Prior knowledge of the LD structure of a
region will allow a more-intelligent and -efficient ap-
proach to association mapping in studies of candidate
genes and perhaps will lead to less-tentative statistical
analysis and more-definitive conclusions (Zondervan and
Cardon 2004). A combination of strategies that include
association mapping and complementary statistical and
bioinformatic analysis will be needed to determine the
significance of the results for GRIN2A and ABAT, as
well as replication in independent samples. The design
of subsequent studies should also include careful consid-
eration of the control samples used for allele- and ge-
notype-frequency comparisons, in terms of their ethnic-
ity, sex, and independence. Chromosome 16p has been
identified by a number of genome screens for autism and
is likely to contain an autism-susceptibility variant. Al-
though the 16p locus has been less consistently replicated
than the chromosome 7 locus, it remains an important
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area for future research (Lamb et al. 2002). However, as
with all multifactorial disorders, progressing from a
broad linkage peak to identifiable functional genetic
variants remains a significant challenge.
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